The seventh batch of centralized procurement of medicines will be put on the agenda, and these varieties have met the conditions

 On November 26, the sixth batch of National Procurement (Insulin Special) officially opened bids and announced the results of the proposed selection.
After a three-day publicity period, on November 30, Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice of the results of the selection", this also means that the sixth batch of national procurement (insulin special) officially "boots"
.
Judging from the official selection results, among domestic pharmaceutical companies, Ganli Pharmaceutical has won the bid for 6 products; United Lab also won the bid for 6 products
.
In addition, Tonghua Dongbao won 5 bids, Hefei Tianmai won 3 bids, Dongyang Sunshine Pharmaceutical won 2 bids, Wanbang Biochemical won 2 bids, and Hisun Pharmaceutical won 1 bid
.
Among multinational pharmaceutical companies, Novo Nordisk has won the bid for 7 products, Eli Lilly won the bid for 5, Poland Baitong won the bid for 3, and Sanofi won the bid for 2 products
.
As a major product in China's pharmaceutical market, hypoglycemic drugs show that in 2020, the terminal sales of public medical institutions in China will be close to 27 billion yuan
.
According to the industry, as the insulin country takes the dust, the tens of billions market is about to be leveraged
.
The sixth batch of National Procurement (Insulin Special) has been "boots off", so can the seventh batch of National Procurement be far behind? According to the rules of previous rounds of national procurement, industry stakeholders have estimated that the seventh batch of national procurement may begin early next year
.
Although the seventh batch of national sourcing has not yet arrived, there are already a large number of varieties that meet the requirements for national sourcing
.
Among them, in the field of anti-tumor drugs, as of now, 10 varieties have met the national centralized procurement requirements
.
These 10 varieties include afatinib oral regular-release dosage form, erlotinib oral regular-release dosage form, lenvatinib oral regular-release dosage form, irinotecan injection, sunitinib oral regular-release dosage form, temozolomide injection, naphthalene Daplatin injection, dasatinib oral regular-release dosage form, vinorelbine injection, trifluridine or tepipyrimine oral regular-release dosage form
.
Among them, afatinib oral constant-release dosage form, the original research company is Boehringer Ingelheim, and there are 7 companies that have been reviewed, namely CSPC, Kelun Pharmaceutical, Hausen Pharmaceutical, Chia Tai Tianqing, Qilu Pharmaceutical, and Yangtze River Pharmaceutical, Shanxiang Pharmaceutical
.
According to statistics, its terminal sales of public medical institutions in China in 2020 will be 435 million yuan
.
Erlotinib oral constant-release dosage form, the original research company is Roche, and there are 6 companies that have been reviewed, namely, Kelun Pharmaceutical, Xinlitai, Hausen Pharmaceutical, Terui Pharmaceutical, Youke Pharmaceutical, and Chuangnuo Pharmaceutical
.
According to statistics, its terminal sales of public medical institutions in China in 2020 will be 245 million yuan
.
Lun cutting imatinib oral often release dosage forms, the original research enterprise as Eisai, has passed assessment enterprises have five, contains CTTQ, special times medicine, Qilu Pharmaceutical, medicine, and so harbinger
.
According to statistics, its terminal sales of public medical institutions in China in 2020 will be 274 million yuan
.
Irinotecan injection, the original research company Pfizer, has passed assessment enterprises have five, contains Hengrui Medicine, Qilu Pharmaceutical, pharmaceutical and other Huiyu
.
According to statistics, its terminal sales of public medical institutions in China in 2020 will be 1.
712 billion yuan
.
According to statistics, in 2020, the total terminal sales of these 10 generic drugs involved in public medical institutions in China will exceed 4.
4 billion yuan
.
Among them, 8 medicines have sales of more than 100 million yuan
.
In addition, among the 10 anti-tumor drugs, Qilu Pharmaceutical has reviewed 7 varieties; CP Tianqing has reviewed 5 varieties; Hausen Pharmaceuticals has 4 varieties reviewed; Kelun Pharmaceutical and CSPC Each company has 3 varieties of reviews
.
It is understood that the policy of centralized drug procurement has an important impact on the drug market
.
From the point of view of the first five batches of medicines, 218 kinds of medicines were covered.
The average price of selected medicines was reduced by 54%, and the cost of medicines saved reached 150 billion yuan
.
Compared with the centralized procurement of chemical drugs, the sixth batch of centralized drug procurement (insulin special) has greatly increased the selection rate.
At the same time, imported products are competing with domestic products on the same stage, and imported products are facing greater pressure to reduce prices
.
According to the industry, whether it is the first five rounds of centralized drug procurement, the sixth batch of centralized drug procurement, or the seventh batch of drug centralized procurement that is about to unfold, the pharmaceutical market is deeply affected by the advancement of centralized drug procurement.
The competition between them is becoming increasingly fierce, but at the same time it also brings real benefits to patients
.